Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q3 2025 · 10-Q
Revenue$0.00$0.00— vs Q3 2024 Net Income-$117.81K-$117.81KN/M vs Q3 2024 EPS Diluted$0.00$0.00— vs Q3 2024 Operating Income-$115,099N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
derived
ended Sep 30, 2025 · filed Nov 10, 2025 · 41 d after period end